Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems
Year: 2008
Type: review
Abstract: Fragile X-associated tremor/ataxia syndrome (FXTAS) is a progressive neurological disorder that affects older adult carriers, predominantly males, of premutation alleles (55 to 200 CGG repeats) of the fragile X (FMR1) gene. Principal features of FXTAS are intention tremor, ataxia, parkinsonism, cognitive decline, and peripheral neuropathy; ancillary features include, autonomic dysfunction, and psychiatric symptoms of anxiety, depression, and disinhibition. Although controlled trials have not been carried out in individuals with FXTAS, there is a significant amount of anecdotal information regarding various treatment modalities. Moreover, there exists a great deal of evidence regarding the efficacy of various medications for treatment of other disorders (eg, Alzheimer disease) that have substantial phenotypic overlap with FXTAS. The current review summarizes what is currently known regarding the symptomatic treatment, or potential for treatment, of FXTAS.
Source: Clinical Interventions in Aging
DOI: 10.2147/cia.s1794
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,836
Funders: Coleman Foundation, National Institutes of Health, Centers for Disease Control and Prevention, National Institute on Aging, National Institute of Neurological Disorders and Stroke, National Center for Research Resources, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: Characterization and Treatment of CNS Abnormalities in Premutation Carriers (4 of, Action tremor & dementia in male carriers of fragile X, Prevalence of FMRI Expansions in Movement Disorders, Research in Intellectual and Developmental Disabilities, Neuro Therapeutics Research Institute, G7822891630, Genotype-Phenotype Relationships in Fragile X Families
OpenAlex ID: W2115628281
